2nd Annual Cancer Immunotherapy Summit

September 2017



Steigenberger Hotel Herrenhof

Herrengasse 10, 1010

About Summit

This Summit is focused on Cancer Immunotherapy, the most promising new cancer treatment approach since the development of the first chemotherapies. This summit brings together leading industry professionals in order to expand the scientific horizons of Cancer Immunotherapy, and discuss the latest advances and improvements in research and development. We will discuss key findings, including critical insights, as well as recommendations for accelerating development in the field.

Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, Scientists, Investigators and Managers specialising in:

  • Oncology
  • Drug Discovery
  • Antibody Engineering
  • Cancer Immunotherapy
  • Hematology
  • Bioinformatics
  • Infection and Immunity
  • Cell & Gene Therapy
  • Tumour Immunology
  • Vaccines Development
  • Clinical Diagnostics
  • Drug Delivery
  • Antibody Discovery
  • Immuno-Oncology
  • Translational Medicine Genetics and Genomics
  • Cancer Genomics
  • Cell Therapy Research
  • Preclinical Development
  • Pathology
Key Practical Learning Points of the Summit

Advanced methods, technological developments and strategies in Cancer Immunotherapy
The success of antibodies in therapeutics and engineering
The true potential of the next generation immune checkpoint pathways
Revolutionary cancer treatment with personalised cancer vaccines
Reinforcing anti-tumour immunity
Biomarkers’ responses
Managing unique immune-mediated adverse reactions and toxicity effects
Progressive genetic engineering techniques
Preclinical and clinical progress in Cancer Immunotherapy
CAR T-Cell Therapy: A game changer in cancer treatment
Regulatory aspects of the EU and the rest of the world
Dr.John Maher, UK

Clinical Immunologist and Immunopathologist 'CAR Mechanics' Research Group

King's College London

Dr. Saso Cemerski, USA

Principal Scientist

Merck Sharp & Dohme Ltd

Dr. Charles Sinclair

Senior Scientist

AstraZeneca, UK

Dr. Maria Groves, UK

Associate Director, Lab Head

Cancer Research UK (CRUK) – MedImmune Alliance

Dr. Armin Sepp, UK

Associate Fellow / Scientific Leader Systems Modeling & Translational Biology Computational & Modeling Sciences


Dr. Kandeepan Ganeshalingam, UK

Executive Director Therapeutic Area Head Oncology European Clinical Development, MRL

Merck Sharp & Dohme Ltd

Dr. Patricia Graef, GE

Associate Scientist

Juno Therapeutics GmbH

Dr. Rer. Nat. Jennifer Altomonte, GE

Principle Investigator Department of Internal Medicine II, Germany

Technical University of Munich

Dr. Matthias Miller, GE

Project Manager

BioNTech AG

Dr. Louis Boon, NE

Chief Scientific Officer


Anja Urbank, GE

Associate Director


Dr. Roger R. Beerli, CH


NBE-Therapeutics Ltd

Dr. Erin Newburn, USA

Field Applications Scientist Manager


Previous Year Attendees
  • National Center for Tumor Diseases (NCT) Heidelberg Germany

  • Hamamatsu Tissue Imaging and Analysis Center, BIOQUANT Germany

    Scientific Director

  • Genentech/Roche Switzerland

    Senior Medical Director, Cancer Immunotherapy

  • QuintilesIMS UK

    Senior Director, Therapeutic Science & Strategy

  • Shire Austria

    Director R&D, Antibody Technology

  • Roche Innovation Center Zurich Switzerland

    Pharmacology Research Area

  • Silenseed LTD Israel


  • University of Southampton UK

    Associate Professor in Oncology, Cancer Sciences Unit

  • GlaxoSmithKline UK

    Head of Discovery & New Technologies, Oncology Cell Therapy Unit, Oncology R&D

  • Novartis Pharma AG Switzerland

    Global Clinical Leader, Oncology Clinical Development

  • AstraZeneca UK

    Medical Director IO-Gmed

  • AMGEN GmbH Germany

    Medical Development Director - TA Bone/Inflammation/Neuroscience

  • GE Healthcare UK

    Product Leader, Cell Therapy

  • NanoTemper Technologies GmbH Munich Germany

    Senior Application Scientist & Sales

  • Paul-Ehrlich-Institut Langen Germany

    Head of Tissue Engineering & Somatic Cell Therapeutics

  • Glythera Ltd UK

    Senior Development Scientist

  • Merck Serono S.p.A Italy

    Biotech Scientific Manager

  • Agensys, an affiliate of Astellas Pharma, Inc USA

    Senior Director Pharmacology

  • eTheRNA immunotherapies NV Belgium

    Chief Scientific Officer

  • Lonza Cologne GmbH Germany

    Sales Specialist

  • IPSEN Innovation SAS France

    Senior Regulatory Product Manager

  • Novartis Pharma GmbH Germany

    Medical Advisor

  • Ablynx NV Belgium

    Senior Research Fellow

  • Charles River UK

    Senior Director Scientific Alliances

  • Orion Clinical Services Ltd. UK

    Associate Medical Director

  • NeoGenomics Laboratories USA

    Vice President Pharma Services, International Sales & Business Development

  • BioNTech Small Molecules GmbH Germany

    Head of Small Molecules

  • Personalis, Inc. USA

    Executive Account Manager D/A/CH

  • Illumina GmbH Germany

    District Marketing Manager, Central Europe

  • Lonza AG Switzerland

    R&T Pharma & Biotech

  • Advanced Cell Diagnostics SRL Italy

    Senior Director Europe, ACD SRL

  • Symphogen Inc. USA

    V.P of Project Management & Clinical Operation

  • Illumina Cambridge Ltd UK

    Director, Business Development

  • Myriad RBM, Inc. USA

    Director, Business Development


    Project Manager

  • Heraeus Deutschland GmbH & Co. KG Germany

    Global Head Projectmanagement Pharmaceutical Ingredients

  • Crown Bioscience Inc USA

    Director of Business Development

  • Invectys SA France


  • Glycotope GmbH Germany


  • Bayer Pharma AG Germany

    Head Clinical Pharmacology Oncology

  • Polypure AS Norway


  • ProteinSimple USA

    Global Pharma and Partners Manager - Simple Plex

more info
Sponsors and Partners




Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner

Media partner